Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
gene editing
5
×
life sciences
5
×
national blog main
boston blog main
boston top stories
national top stories
san francisco blog main
san francisco top stories
editas medicine
boston
boulder/denver blog main
boulder/denver top stories
ceo
clinical study
commissioner
crispr
crispr-cas9
detroit blog main
detroit top stories
enzyme
fda
genome editing
ipo
katrine bosley
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
scott gottlieb
seattle blog main
seattle top stories
shutdown
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
What
medicine
5
×
crispr
editas
editing
gene
bio
cas
ceo
humans
katrine
roundup
therapeutics
trial
allergan
beam
benefit
big
biopharma
blessing
bosley
bosley's
bosley’s
bridge
bucks
car
celgene
check
clinical
colleagues
crime
cusp
depart
departure
editor
exit
exome
experimental
founders
going
gotten
Language
Current search:
medicine
×
" life sciences "
×
" gene editing "
×
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M